IDP Education rejects $2.50 Blackstone takeover offer
IDP Education (ASX:IEL) rejected an unsolicited cash proposal from Blackstone Singapore to acquire 100% of the company for $2.50 per share.
IDP Education (ASX:IEL) rejected an unsolicited cash proposal from Blackstone Singapore to acquire 100% of the company for $2.50 per share.
RBA Governor Michele Bullock stated that the national unemployment rate must rise to between 4.5% and 5% to successfully rein in persistent inflation.
Shopify (NYSE:SHOP) shares rose after the company announced a partnership with Meta Platforms’ AI agent Muse to enable agentic checkout using Shop Pay across Shopify stores.
Filana Therapeutics (NASDAQ:FLNA) shares rose after the U.S. Food and Drug Administration lifted a clinical hold on its experimental drug simufilam for epilepsy linked to tuberous sclerosis complex.
Compass Therapeutics (NASDAQ:CMPX) shares declined after the U.S. Food and Drug Administration recommended an additional trial before the company submits a marketing application for tovecimig.
Amgen (NASDAQ:AMGN) said its experimental drug dazodalibep met the primary goal in a late-stage trial evaluating treatment for Sjogren’s disease.
Nutanix (NASDAQ:NTNX) acquired Ryax Technologies, a France-based AI-driven compute orchestration and management platform company, to expand its artificial intelligence infrastructure capabilities.
Oil prices declined to two-week lows on Tuesday as expectations for Gulf supply recovery improved following developments involving Iran and Saudi Arabia.
Endeavour Silver (NYSE:EXK) temporarily halted its primary ball mill at the Guanacevi Mine after identifying a mechanical issue on September 21, 2026.
Celldex Therapeutics (NASDAQ:CLDX) reported positive topline results from two Phase 3 trials evaluating barzolvolimab in adults with chronic spontaneous urticaria.
GET YOUR GRAFA EDGE NOW
We'll switch on a 30-day Edge trial as a welcome gift
Got a second for a cookie? 🍪Essential cookies keep Grafa running smoothly. A few optional ones help us see what's working so we can make it better. You're in control — change your mind any time. Cookie policy · Privacy policy